DIVA Laboratories (4153) reported revenue of NT$85.7 million for Oct 2026, +41.7% year on year and +0.0% from the previous month. Revenue for Jan–Oct 2026 was NT$802 million (+14.6% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 83 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$85.7 million | +41.7% | +0.0% |
| Sep 2026 | NT$85.7 million | +38.2% | +7.6% |
| Aug 2026 | NT$79.6 million | +11.8% | -4.1% |
| Jul 2026 | NT$83.1 million | +30.2% | -12.8% |
| Jun 2026 | NT$95.2 million | +40.2% | +25.8% |
| May 2026 | NT$75.7 million | -4.0% | +2.1% |
| Apr 2026 | NT$74.1 million | -16.0% | -17.0% |
| Mar 2026 | NT$89.3 million | +14.6% | +39.0% |
| Feb 2026 | NT$64.3 million | -12.9% | -7.2% |
| Jan 2026 | NT$69.3 million | +25.2% | -28.6% |
| Dec 2025 | NT$97 million | +14.6% | +34.3% |
| Nov 2025 | NT$72.2 million | +0.6% | +19.5% |
| Oct 2025 | NT$60.5 million | -9.5% | -2.5% |
| Sep 2025 | NT$62 million | -4.5% | -12.9% |
| Aug 2025 | NT$71.2 million | +2.8% | +11.7% |
| Jul 2025 | NT$63.8 million | +7.3% | -6.1% |
| Jun 2025 | NT$67.9 million | -10.4% | -13.9% |
| May 2025 | NT$78.9 million | +18.0% | -10.6% |
| Apr 2025 | NT$88.2 million | +9.7% | +13.2% |
| Mar 2025 | NT$78 million | +3.0% | +5.6% |
| Feb 2025 | NT$73.8 million | -2.0% | +33.5% |
| Jan 2025 | NT$55.3 million | -22.5% | -34.7% |
| Dec 2024 | NT$84.7 million | +17.7% | +18.0% |
| Nov 2024 | NT$71.8 million | +4.4% | +7.5% |
| Oct 2024 | NT$66.8 million | +4.1% | +2.8% |
Jan–Oct 2026 cumulative: NT$802 million (+14.6% YoY)
Other Biotech & Medical companies
Compare with peers: DIVA Laboratories vs PEC / DIVA Laboratories vs Lotus Pharm / DIVA Laboratories vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16